Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Stocks like Jio Financial Services, Can Fin Homes, Seshasayee Paper, Supreme Petrochem, 5paisa Capital, ICICI Lombard General ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

The company's expanding product pipeline and strong fundamentals make it a compelling play in the pharmaceutical sector, the brokerage said. Share price of Zydus Lifesciences fell as much as 0.77% to ...

Brokerage firm Nomura has upgraded shares of Zydus Lifesciences Ltd. to "buy" from its earlier rating of "hold" and also raised its price target to ₹1,140 from ₹1,030 earlier. In a note on Thursday, ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus’ strategic investments in the new drug applications portfolio. It “will set the ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio. It "will set the way for ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...